Home » News » CROs/Service Providers » Mapi completes acquisition of Optum Life Sciences services

Mapi completes acquisition of Optum Life Sciences services

Tuesday, January 6, 2015

Mapi, a global health research and commercialization services company, has completed the acquisition of select Optum Life Sciences services, including North American and European Regulatory Consulting, Late Phase CRO and European Health Economics and Outcomes Research (HEOR) teams.

“Today’s therapeutics market is driven by patient outcomes and treatment value proven by real-world evidence. This acquisition enables Mapi to strengthen our industry-leading expertise and integrated solutions to help our clients accelerate market adoption of their novel therapeutics,” said James Karis, Mapi’s CEO. “With this acquisition, we also are the largest independent company exclusively dedicated to health research and commercialization services.”

With the addition of these new services and experts, Mapi has expanded its team across the Americas, Europe and Asia Pacific. Mapi has expanded its experience in strategic regulatory services, epidemiology, strategic market access, health economics outcomes research, patient centered outcomes, language services, patient insights, direct to patient support and real-world evidence.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!